<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01764945</url>
  </required_header>
  <id_info>
    <org_study_id>1220.46</org_study_id>
    <secondary_id>2012-000687-22</secondary_id>
    <nct_id>NCT01764945</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions</brief_title>
  <official_title>Relative Bioavailability of BI 201335 (Capsule) Compared to Three Different Oral Solutions of BI 201335 Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Four-way Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the relative bioavailability of two
      different doses of BI 201335, administered as soft gelatine capsule in comparison to the
      equivalent doses of three different oral solution per dose of BI 201335.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-âˆž</measure>
    <time_frame>-1:00, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 9:00, 10:00, 12:00, 24:00, 48:00, 72:00, 96:00, 120:00 h (hours) after administration of faldaprevir on Day 1.</time_frame>
    <description>Area under the concentration-time curve of the analyte (faldaprevir) in plasma over the time interval from 0 extrapolated to infinity.
The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>-1:00, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 9:00, 10:00, 12:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after administration of faldaprevir on Day 1.</time_frame>
    <description>Maximum measured concentration of the analyte (faldaprevir) in plasma. The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz</measure>
    <time_frame>-1:00, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 9:00, 10:00, 12:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after administration of faldaprevir on Day 1.</time_frame>
    <description>Area under the concentration-time curve of the analyte (faldaprevir) in plasma over the time interval from 0 to the time of the last quantifiable data point.
The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1 BI 201335</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 BI 201335</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 (Reference)</intervention_name>
    <description>soft gelatine capsule, oral administration</description>
    <arm_group_label>1 BI 201335</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 (Test)</intervention_name>
    <description>oral solution 3</description>
    <arm_group_label>1 BI 201335</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 (Test)</intervention_name>
    <description>oral solution 3</description>
    <arm_group_label>2 BI 201335</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 (Test)</intervention_name>
    <description>oral solution 2</description>
    <arm_group_label>1 BI 201335</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 (Reference)</intervention_name>
    <description>soft gelatine capsule, oral administration</description>
    <arm_group_label>2 BI 201335</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 (Test)</intervention_name>
    <description>oral solution 1</description>
    <arm_group_label>2 BI 201335</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 (Test)</intervention_name>
    <description>oral solution 1</description>
    <arm_group_label>1 BI 201335</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 (Test)</intervention_name>
    <description>oral solution 2</description>
    <arm_group_label>2 BI 201335</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy male and female subjects

        Exclusion criteria:

        Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.46.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <results_first_submitted>July 3, 2015</results_first_submitted>
  <results_first_submitted_qc>July 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 31, 2015</results_first_posted>
  <last_update_submitted>July 3, 2015</last_update_submitted>
  <last_update_submitted_qc>July 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>40mg Faldaprevir: Sequence Group ADBC</title>
          <description>40 mg group: The reference treatment was a single 40 mg dose of faldaprevir soft gelatine capsule (treatment A) and the test treatments were single 40 mg doses of 3 different faldaprevir oral solutions (treatments B, C, and D).
The order of treatment administration in this sequence group is ADBC with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="P2">
          <title>40mg Faldaprevir: Sequence Group BACD</title>
          <description>40 mg group: The reference treatment was a single 40 mg dose of faldaprevir soft gelatine capsule (treatment A) and the test treatments were single 40 mg doses of 3 different faldaprevir oral solutions (treatments B, C, and D).
The order of treatment administration in this sequence group is BACD with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="P3">
          <title>40mg Faldaprevir: Sequence Group CBDA</title>
          <description>40 mg group: The reference treatment was a single 40 mg dose of faldaprevir soft gelatine capsule (treatment A) and the test treatments were single 40 mg doses of 3 different faldaprevir oral solutions (treatments B, C, and D).
The order of treatment administration in this sequence group is CBDA with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="P4">
          <title>40mg Faldaprevir: Sequence Group DCAB</title>
          <description>40 mg group: The reference treatment was a single 40 mg dose of faldaprevir soft gelatine capsule (treatment A) and the test treatments were single 40 mg doses of 3 different faldaprevir oral solutions (treatments B, C, and D).
The order of treatment administration in this sequence group is DCAB with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="P5">
          <title>120mg Faldaprevir: Sequence Group EHFG</title>
          <description>120 mg group: The reference treatment was a single 120 mg dose (consisting of three 40 mg faldaprevir soft gelatine capsules, treatment E) and the test treatments were single 120 mg doses of 3 different faldaprevir oral solutions (treatments F, G, and H).
The order of treatment administration in this sequence group is EHFG with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="P6">
          <title>120mg Faldaprevir: Sequence Group FEGH</title>
          <description>120 mg group: The reference treatment was a single 120 mg dose (consisting of three 40 mg faldaprevir soft gelatine capsules, treatment E) and the test treatments were single 120 mg doses of 3 different faldaprevir oral solutions (treatments F, G, and H).
The order of treatment administration in this sequence group is FEGH with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="P7">
          <title>120mg Faldaprevir: Sequence Group GFHE</title>
          <description>120 mg group: The reference treatment was a single 120 mg dose (consisting of three 40 mg faldaprevir soft gelatine capsules, treatment E) and the test treatments were single 120 mg doses of 3 different faldaprevir oral solutions (treatments F, G, and H).
The order of treatment administration in this sequence group is GFHE with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="P8">
          <title>120mg Faldaprevir: Sequence Group HGEF</title>
          <description>120 mg group: The reference treatment was a single 120 mg dose (consisting of three 40 mg faldaprevir soft gelatine capsules, treatment E) and the test treatments were single 120 mg doses of 3 different faldaprevir oral solutions (treatments F, G, and H).
The order of treatment administration in this sequence group is HGEF with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This trial was an open-label study consisting of two (40mg and 120mg Faldaprevir) 4-way crossover groups. All subjects were to receive 4 treatments: either treatments A, B, C, and D (20 subjects) or treatments E, F, G, and H (36 subjects). Subjects were randomised to 1 of the 4 treatment sequences for each dose group to be tested in a 1:1:1:1 ratio</population>
      <group_list>
        <group group_id="B1">
          <title>40mg Faldaprevir: Sequence Group ADBC</title>
          <description>40 mg group: The reference treatment was a single 40 mg dose of faldaprevir soft gelatine capsule (treatment A) and the test treatments were single 40 mg doses of 3 different faldaprevir oral solutions (treatments B, C, and D).
The order of treatment administration in this sequence group is ADBC with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="B2">
          <title>40mg Faldaprevir: Sequence Group BACD</title>
          <description>40 mg group: The reference treatment was a single 40 mg dose of faldaprevir soft gelatine capsule (treatment A) and the test treatments were single 40 mg doses of 3 different faldaprevir oral solutions (treatments B, C, and D).
The order of treatment administration in this sequence group is BACD with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="B3">
          <title>40mg Faldaprevir: Sequence Group CBDA</title>
          <description>40 mg group: The reference treatment was a single 40 mg dose of faldaprevir soft gelatine capsule (treatment A) and the test treatments were single 40 mg doses of 3 different faldaprevir oral solutions (treatments B, C, and D).
The order of treatment administration in this sequence group is CBDA with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="B4">
          <title>40mg Faldaprevir: Sequence Group DCAB</title>
          <description>40 mg group: The reference treatment was a single 40 mg dose of faldaprevir soft gelatine capsule (treatment A) and the test treatments were single 40 mg doses of 3 different faldaprevir oral solutions (treatments B, C, and D).
The order of treatment administration in this sequence group is DCAB with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="B5">
          <title>120mg Faldaprevir: Sequence Group EHFG</title>
          <description>120 mg group: The reference treatment was a single 120 mg dose (consisting of three 40 mg faldaprevir soft gelatine capsules, treatment E) and the test treatments were single 120 mg doses of 3 different faldaprevir oral solutions (treatments F, G, and H).
The order of treatment administration in this sequence group is EHFG with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="B6">
          <title>120mg Faldaprevir: Sequence Group FEGH</title>
          <description>120 mg group: The reference treatment was a single 120 mg dose (consisting of three 40 mg faldaprevir soft gelatine capsules, treatment E) and the test treatments were single 120 mg doses of 3 different faldaprevir oral solutions (treatments F, G, and H).
The order of treatment administration in this sequence group is FEGH with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="B7">
          <title>120mg Faldaprevir: Sequence Group GFHE</title>
          <description>120 mg group: The reference treatment was a single 120 mg dose (consisting of three 40 mg faldaprevir soft gelatine capsules, treatment E) and the test treatments were single 120 mg doses of 3 different faldaprevir oral solutions (treatments F, G, and H).
The order of treatment administration in this sequence group is GFHE with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="B8">
          <title>120mg Faldaprevir: Sequence Group HGEF</title>
          <description>120 mg group: The reference treatment was a single 120 mg dose (consisting of three 40 mg faldaprevir soft gelatine capsules, treatment E) and the test treatments were single 120 mg doses of 3 different faldaprevir oral solutions (treatments F, G, and H).
The order of treatment administration in this sequence group is HGEF with washout phases of at least 14 days between drug administrations.
Oral administration (under fed conditions, i.e. following a high-fat breakfast).</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="9"/>
            <count group_id="B8" value="9"/>
            <count group_id="B9" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" spread="5.3"/>
                    <measurement group_id="B2" value="39.8" spread="5.1"/>
                    <measurement group_id="B3" value="38.0" spread="10.2"/>
                    <measurement group_id="B4" value="44.4" spread="4.2"/>
                    <measurement group_id="B5" value="33.9" spread="9.7"/>
                    <measurement group_id="B6" value="38.6" spread="9.6"/>
                    <measurement group_id="B7" value="39.4" spread="8.1"/>
                    <measurement group_id="B8" value="34.9" spread="9.5"/>
                    <measurement group_id="B9" value="38.1" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-âˆž</title>
        <description>Area under the concentration-time curve of the analyte (faldaprevir) in plasma over the time interval from 0 extrapolated to infinity.
The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>-1:00, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 9:00, 10:00, 12:00, 24:00, 48:00, 72:00, 96:00, 120:00 h (hours) after administration of faldaprevir on Day 1.</time_frame>
        <population>Pharmacokinetic analysis set (PK set) includes all subjects who provided evaluable data for at least 1 evaluable observation for a PK endpoint in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Faldaprevir: Treatment A</title>
            <description>40 mg faldaprevir soft gelatine capsule (reference).</description>
          </group>
          <group group_id="O2">
            <title>40mg Faldaprevir: Treatment B</title>
            <description>40 mg faldaprevir oral solution 1</description>
          </group>
          <group group_id="O3">
            <title>40mg Faldaprevir: Treatment C</title>
            <description>40 mg faldaprevir oral solution 2</description>
          </group>
          <group group_id="O4">
            <title>40mg Faldaprevir: Treatment D</title>
            <description>40 mg faldaprevir oral solution 3</description>
          </group>
          <group group_id="O5">
            <title>120mg Faldaprevir: Treatment E</title>
            <description>120 mg faldaprevir soft gelatine capsule (reference).</description>
          </group>
          <group group_id="O6">
            <title>120mg Faldaprevir: Treatment F</title>
            <description>120 mg faldaprevir oral solution 1</description>
          </group>
          <group group_id="O7">
            <title>120mg Faldaprevir: Treatment G</title>
            <description>120 mg faldaprevir oral solution 2</description>
          </group>
          <group group_id="O8">
            <title>120mg Faldaprevir: Treatment H</title>
            <description>120 mg faldaprevir oral solution 3</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-âˆž</title>
          <description>Area under the concentration-time curve of the analyte (faldaprevir) in plasma over the time interval from 0 extrapolated to infinity.
The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic analysis set (PK set) includes all subjects who provided evaluable data for at least 1 evaluable observation for a PK endpoint in at least 1 treatment period.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3960" spread="32.3"/>
                    <measurement group_id="O2" value="3400" spread="28.5"/>
                    <measurement group_id="O3" value="3350" spread="28.4"/>
                    <measurement group_id="O4" value="3420" spread="30.4"/>
                    <measurement group_id="O5" value="15000" spread="34.5"/>
                    <measurement group_id="O6" value="13900" spread="38.8"/>
                    <measurement group_id="O7" value="14500" spread="38.3"/>
                    <measurement group_id="O8" value="14100" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 40 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment B : treatment A).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>82.58</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>19.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.69</ci_lower_limit>
            <ci_upper_limit>92.54</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 40 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment C : treatment A).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>83.34</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.65</ci_lower_limit>
            <ci_upper_limit>94.30</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 40 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment D : treatment A).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>83.92</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>19.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>74.69</ci_lower_limit>
            <ci_upper_limit>94.28</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 120 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment F : treatment E).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>92.90</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>10.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.94</ci_lower_limit>
            <ci_upper_limit>97.04</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 120 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment G : treatment E).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>96.37</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.55</ci_lower_limit>
            <ci_upper_limit>101.43</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 120 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment H : treatment E).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>94.44</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.88</ci_lower_limit>
            <ci_upper_limit>99.24</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum measured concentration of the analyte (faldaprevir) in plasma. The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>-1:00, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 9:00, 10:00, 12:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after administration of faldaprevir on Day 1.</time_frame>
        <population>PK set.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Faldaprevir: Treatment A</title>
            <description>40 mg faldaprevir soft gelatine capsule (reference).</description>
          </group>
          <group group_id="O2">
            <title>40mg Faldaprevir: Treatment B</title>
            <description>40 mg faldaprevir oral solution 1</description>
          </group>
          <group group_id="O3">
            <title>40mg Faldaprevir: Treatment C</title>
            <description>40 mg faldaprevir oral solution 2</description>
          </group>
          <group group_id="O4">
            <title>40mg Faldaprevir: Treatment D</title>
            <description>40 mg faldaprevir oral solution 3</description>
          </group>
          <group group_id="O5">
            <title>120mg Faldaprevir: Treatment E</title>
            <description>120 mg faldaprevir soft gelatine capsule (reference).</description>
          </group>
          <group group_id="O6">
            <title>120mg Faldaprevir: Treatment F</title>
            <description>120 mg faldaprevir oral solution 1</description>
          </group>
          <group group_id="O7">
            <title>120mg Faldaprevir: Treatment G</title>
            <description>120 mg faldaprevir oral solution 2</description>
          </group>
          <group group_id="O8">
            <title>120mg Faldaprevir: Treatment H</title>
            <description>120 mg faldaprevir oral solution 3</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum measured concentration of the analyte (faldaprevir) in plasma. The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>PK set.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" spread="36.0"/>
                    <measurement group_id="O2" value="65.4" spread="39.0"/>
                    <measurement group_id="O3" value="64.0" spread="40.4"/>
                    <measurement group_id="O4" value="69.7" spread="28.1"/>
                    <measurement group_id="O5" value="625.0" spread="47.3"/>
                    <measurement group_id="O6" value="481.0" spread="47.1"/>
                    <measurement group_id="O7" value="488.0" spread="52.1"/>
                    <measurement group_id="O8" value="485.0" spread="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 40 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment B : treatment A).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>74.07</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>21.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65.44</ci_lower_limit>
            <ci_upper_limit>83.83</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 40 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment C : treatment A).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>73.23</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>26.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>63.33</ci_lower_limit>
            <ci_upper_limit>84.68</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 40 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment D : treatment A).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>78.76</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68.94</ci_lower_limit>
            <ci_upper_limit>89.99</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 120 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment F : treatment E).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>78.30</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>71.42</ci_lower_limit>
            <ci_upper_limit>85.84</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 120 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment G : treatment E).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>78.43</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>30.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.54</ci_lower_limit>
            <ci_upper_limit>88.46</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 120 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment H : treatment E).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>78.09</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.35</ci_lower_limit>
            <ci_upper_limit>87.94</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-tz</title>
        <description>Area under the concentration-time curve of the analyte (faldaprevir) in plasma over the time interval from 0 to the time of the last quantifiable data point.
The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>-1:00, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 9:00, 10:00, 12:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after administration of faldaprevir on Day 1.</time_frame>
        <population>PK set.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Faldaprevir: Treatment A</title>
            <description>40 mg faldaprevir soft gelatine capsule (reference).</description>
          </group>
          <group group_id="O2">
            <title>40mg Faldaprevir: Treatment B</title>
            <description>40 mg faldaprevir oral solution 1</description>
          </group>
          <group group_id="O3">
            <title>40mg Faldaprevir: Treatment C</title>
            <description>40 mg faldaprevir oral solution 2</description>
          </group>
          <group group_id="O4">
            <title>40mg Faldaprevir: Treatment D</title>
            <description>40 mg faldaprevir oral solution 3</description>
          </group>
          <group group_id="O5">
            <title>120mg Faldaprevir: Treatment E</title>
            <description>120 mg faldaprevir soft gelatine capsule (reference).</description>
          </group>
          <group group_id="O6">
            <title>120mg Faldaprevir: Treatment F</title>
            <description>120 mg faldaprevir oral solution 1</description>
          </group>
          <group group_id="O7">
            <title>120mg Faldaprevir: Treatment G</title>
            <description>120 mg faldaprevir oral solution 2</description>
          </group>
          <group group_id="O8">
            <title>120mg Faldaprevir: Treatment H</title>
            <description>120 mg faldaprevir oral solution 3</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz</title>
          <description>Area under the concentration-time curve of the analyte (faldaprevir) in plasma over the time interval from 0 to the time of the last quantifiable data point.
The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>PK set.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3020" spread="29.4"/>
                    <measurement group_id="O2" value="2600" spread="32.9"/>
                    <measurement group_id="O3" value="2520" spread="38.3"/>
                    <measurement group_id="O4" value="2550" spread="34.3"/>
                    <measurement group_id="O5" value="14200" spread="35.2"/>
                    <measurement group_id="O6" value="12900" spread="39.4"/>
                    <measurement group_id="O7" value="13400" spread="38.0"/>
                    <measurement group_id="O8" value="13100" spread="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 40 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment B : treatment A).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>82.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>75.98</ci_lower_limit>
            <ci_upper_limit>88.55</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 40 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment C : treatment A).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>80.93</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>74.58</ci_lower_limit>
            <ci_upper_limit>87.83</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 40 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment D : treatment A).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>79.60</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>10.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>74.84</ci_lower_limit>
            <ci_upper_limit>84.67</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 120 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment F : treatment E).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>91.59</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.53</ci_lower_limit>
            <ci_upper_limit>95.84</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 120 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment G : treatment E).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>94.38</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.76</ci_lower_limit>
            <ci_upper_limit>99.24</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison of 120 mg faldaprevir soft gelatine capsules compared with the equivalent dose of an oral solution.
(treatment H : treatment E).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing).</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>92.91</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.42</ci_lower_limit>
            <ci_upper_limit>97.63</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and concomitant medication will be evaluated continuously from first drug administration until the end-of-study examination (up to 5 weeks). AEs persisting after trial completion must be followed up, until they have normalised.</time_frame>
      <desc>Subjects were required to report spontaneously any AEs throughout the clinical trial. In addition, each volunteer was assessed regularly by the medical staff throughout the clinical trial as well as at the end of observation and whenever necessary as deemed by the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>40mg Faldaprevir: Treatment A</title>
          <description>40 mg faldaprevir soft gelatine capsule (reference).</description>
        </group>
        <group group_id="E2">
          <title>40mg Faldaprevir: Treatment B</title>
          <description>40 mg faldaprevir oral solution 1.</description>
        </group>
        <group group_id="E3">
          <title>40mg Faldaprevir: Treatment C</title>
          <description>40 mg faldaprevir oral solution 2.</description>
        </group>
        <group group_id="E4">
          <title>40mg Faldaprevir: Treatment D</title>
          <description>40 mg faldaprevir oral solution 3.</description>
        </group>
        <group group_id="E5">
          <title>120mg Faldaprevir: Treatment E</title>
          <description>120 mg faldaprevir soft gelatine capsule (reference).</description>
        </group>
        <group group_id="E6">
          <title>120mg Faldaprevir: Treatment F</title>
          <description>120 mg faldaprevir oral solution 1.</description>
        </group>
        <group group_id="E7">
          <title>120mg Faldaprevir: Treatment G</title>
          <description>120 mg faldaprevir oral solution 2.</description>
        </group>
        <group group_id="E8">
          <title>120mg Faldaprevir: Treatment H</title>
          <description>120 mg faldaprevir oral solution 3.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BIâ€™s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

